



**Comparison of patients diagnosed with gonorrhoea through  
community screening with those self-presenting to the  
genito-urinary medicine clinic**

|                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal:                        | <i>BMJ Open</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Manuscript ID:                  | bmjopen-2014-004862                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Article Type:                   | Research                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Date Submitted by the Author:   | 15-Jan-2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Complete List of Authors:       | Cook, Penny; University of Salford, School of Health Sciences<br>Evans-Jones, John; Countess of Chester Hospital NHS Foundation Trust, Genito-Urinary Medicine<br>Mallinson, Harry; Aintree University Hospitals NHS Foundation Trust, Microbiology Laboratory<br>Wood, Martyn; Mid-Cheshire Hospitals NHS Foundation Trust, Centre for Sexual Health and Contraception<br>Alloba, Fath; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Genito-Urinary Medicine<br>Jones, Kathy; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Genito-Urinary Medicine<br>Strodtbeck, Sara; Liverpool Community Health NHS Trust,<br>Hanna-Bashara, Layla; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Department of Dermatology |
| <b>Primary Subject Heading</b>: | Sexual health                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Secondary Subject Heading:      | Infectious diseases, Epidemiology, Public health                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Keywords:                       | GENITOURINARY MEDICINE, socioeconomic status, Mass screening, Community Health Services, Residence Characteristics, Neisseria gonorrhoeae                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

SCHOLARONE™  
Manuscripts

1  
2  
3 Title:

4  
5  
6 **Comparison of patients diagnosed with gonorrhoea through community screening with**  
7  
8 **those self-presenting to the genito-urinary medicine clinic.**  
9

10  
11  
12 Penny A. Cook<sup>1</sup>

13 John Evans-Jones<sup>2</sup>

14  
15  
16 Harry Mallinson<sup>3</sup>

17  
18  
19 Martyn Wood<sup>4</sup>

20  
21  
22 Fath Alloba<sup>5</sup>

23  
24  
25 Kathy Jones<sup>5</sup>

26  
27  
28 Sara Strodbeck<sup>6</sup>

29  
30  
31 Layla Hanna-Bashara<sup>7</sup>

32  
33  
34 <sup>1</sup>Correspondence: Penny A. Cook

35  
36 University of Salford

37  
38 School of Health Sciences

39  
40 Allerton Building

41  
42 Salford M6 6PU, UK

43  
44 p.a.cook@salford.ac.uk  
45  
46  
47

48  
49  
50 <sup>2</sup>John Evans-Jones

51  
52  
53 Countess of Chester Hospital NHS Foundation Trust

54  
55 Countess of Chester Health Park  
56

1  
2  
3 Liverpool Road  
4  
5  
6 Chester CH2 1UL  
7  
8  
9

10 <sup>3</sup>Harry Mallinson  
11  
12 Retired Consultant Clinical Scientist  
13  
14 Microbiology Laboratory  
15  
16  
17 Aintree University Hospitals NHS Foundation Trust  
18  
19  
20 hm@haytor1.plus.com  
21  
22  
23

24 <sup>4</sup>Martyn Wood  
25  
26  
27 Centre for Sexual Health and Contraception  
28  
29 Mid-Cheshire Hospitals NHS Foundation Trust  
30  
31  
32 Middlewich Road  
33  
34 Crewe  
35  
36 Cheshire  
37  
38  
39 CW1 4QJ  
40  
41  
42

43 <sup>5</sup>Fath Alloba, Kathy Jones  
44  
45  
46 Royal Liverpool and Broadgreen University Hospitals NHS Trust  
47  
48 Royal Liverpool University Hospital  
49  
50  
51 Prescot Street  
52  
53 Liverpool  
54  
55  
56 L7 8XP  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 <sup>6</sup>Sara Strottbeck

7  
8 Liverpool Community Health NHS Trust

9  
10 Citrus House

11  
12 40-46 Dale Street

13  
14 Liverpool L2 5SF

15  
16  
17  
18  
19  
20 <sup>7</sup>Layla Hanna-Bashara

21  
22 Department of Dermatology

23  
24 Royal Liverpool and Broadgreen University Hospitals NHS Trust

25  
26 Broadgreen Hospital

27  
28 Kent lodge

29  
30 Thomas drive

31  
32 Liverpool L14 3LB

33  
34  
35  
36  
37  
38  
39 Running head: Testing for gonorrhoea in the community

40  
41  
42  
43 *Key words: Neisseria gonorrhoeae, Mass Screening, Residence Characteristics,*

44  
45  
46 *Community Health Services, socioeconomic status*

47  
48  
49  
50  
51 Word Count: 2381

## ABSTRACT

**Objectives:** To compare the clinical, socioeconomic and demographic characteristics of individuals diagnosed with *Neisseria gonorrhoea* (NG) in the community using concomitant a Nucleic Acid Amplification Test (NAAT, AptimaCombo2) testing as part of the (community-based) United Kingdom Chlamydia Screening Programme (CSP), with those diagnosed in hospital-based Genitourinary Medicine (GUM) services.

**Design:** A retrospective case note review of all 643 patients treated for NG at a GUM in north west England (01/2007—04/2009).

**Participants:** All 643 treated for NG (including CSP cases, since all cases were referred to GUM for treatment). Limited data were available for 13 CSP cases who failed to attend GUM.

**Primary outcome measure:** Whether the case was detected in the community or GUM.

Predictors were demographics (age, gender, postcode for deprivation analysis), sexual history (e.g. number of partners) and clinical factors (e.g. culture positivity).

**Results:** 131 cases were diagnosed by CSP (13 of whom did not attend GUM). A further 4 cases were contacts of these. The GUM caseload was thus inflated by 23% (from 521 to 643).

Community cases were overwhelmingly female (85% vs 27% in GUM,  $P < 0.001$ ) and younger (87% females were  $< 25$ y vs 70% GUM females,  $p = 0.001$ ). Logistic regression analysis restricted to the target age of the CSP ( $< 25$ y) revealed that CSP cases, compared to GUM cases, were more likely to reside in deprived areas (adjusted OR = 5.6, 95%CI 1.4—21.8 and 5.3, CI 1.7—16.6 for the most and second most deprived group respectively, compared to the averagely deprived group,  $p = 0.037$ ) and be asymptomatic (adjOR=1.9, CI 1.1—3.4, 0.02).

**Conclusion**

1  
2  
3 Community screening for NG led to a 79% increase in the number of infections detected in  
4  
5 women aged <25y. Screening is targeted at young people, and tends to disproportionately attract  
6  
7 young women, a group under-represented at GUM. Screening also contributed further to case  
8  
9 detection in deprived areas.  
10  
11  
12  
13

## 14 15 **ARTICLE SUMMARY**

### 16 17 18 **Strengths and limitations of this study**

- 19 • Little attention has been paid to the possibility that screening programmes improve  
20  
21 diagnosis in populations that would not traditionally attend GUM. This study fills a gap  
22  
23 in knowledge about the socioeconomic status of those identified in the different settings.  
24  
25
- 26 • NG cases were over-represented in particular relatively deprived areas of the study area,  
27  
28 as shown by geodemographic profiling (the Mosaic tool).  
29  
30
- 31 • Community screening for NG contributed extra female cases, asymptomatic male cases  
32  
33 and cases from relatively more deprived areas, which may have otherwise remained  
34  
35 undetected.  
36  
37
- 38 • As a retrospective review of cases, there were no controls, limiting the conclusions from  
39  
40 this study.  
41  
42
- 43 • The deprivation results and Mosaic groups should be interpreted with caution, since such  
44  
45 area-level measures of deprivation may not represent the characteristics of individuals.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Nucleic acid amplification tests (NAATs) have greater sensitivity than culture and are now widely used to diagnose sexually transmitted infections (STIs), including *Neisseria gonorrhoeae* (NG) using non-invasive and easily transportable samples. However, in low prevalence populations where an NG NAAT might not display a positive predictive value exceeding 90%, positive samples are now recommended to be subjected to confirmatory testing.[1]

The UK national Chlamydia Screening Programme (CSP) is an opportunistic screening programme which uses NAATs for *Chlamydia trachomatis* (CT). The programme is targeted at all young people aged under 25 years (although tends to be predominantly taken up by women[2]), and based in community settings such as pharmacies, community contraception clinics, primary care, schools and colleges. Concomitant NAAT screening for both CT and NG (Aptima Combo 2 assay, Gen-Probe Inc, San Diego, CA, USA) using either self-taken or clinician samples was introduced into the study area CSP in 2004 at the same cost as a CT test alone. Cases of NG identified are subsequently referred to the specialist Genitourinary Medicine (GUM) service for parenteral treatment, specialist partner notification and antibiotic sensitivity testing. The overall detection of NG has increased in areas where such an approach has been implemented.[3-5]

Previous studies of NG epidemiology have been based on GUM clinic populations [6-8] and therefore less is known about the characteristics of cases that are detected outside GUM. Such analysis that does exist confirms the characteristics that would be expected based on the target and settings of the screening programme (i.e. young women)[5]. Little attention has been paid to

1  
2  
3 the possibility that screening programmes improve diagnosis in populations that would not  
4  
5 traditionally attend GUM. This study compares the demographic and clinical profile of NG cases  
6  
7 detected by the CSP with that of a GUM clinic population with a specific aim to fill the gap in  
8  
9 knowledge about the socioeconomic status of those identified in the different settings.  
10  
11  
12  
13

## 14 15 **METHODS**

16  
17 A cross-sectional retrospective case note review was completed of all cases of complicated and  
18  
19 uncomplicated NG attending a GUM service between 01/01/07 and 31/03/09, identified from  
20  
21 GUM clinic records (using the Sexual Health and HIV Activity Property Type—SHHAPT—  
22  
23 surveillance report codes). The GUM is located in a large city, adjacent to some of the most  
24  
25 deprived areas in England. The referral route was recorded as follows: diagnosed in the open-  
26  
27 access GUM clinic; referred from the CSP; a contact of an NG case; referred from general  
28  
29 practice. Demographic data collected included: postcode (to allow allocation of an area-based  
30  
31 deprivation measure and use of a postcode classification tool, Mosaic, that uses over 400 data  
32  
33 indicators to classify all UK citizens into fifteen population types, ‘Mosaic groups’), gender, age  
34  
35 (either <25years, the target age for the CSP, or ≥25years) and ethnicity. Clinical data were:  
36  
37 symptoms of NG; NG culture results; CT test result. Clinic policy was for NG culture samples to  
38  
39 be recommended as a minimum of one sample per NG from up to four anatomical sites in total:  
40  
41 pharynx, rectum, cervix (women only), and urethra. Culture result was recorded as ‘positive’ if  
42  
43 one or more was positive, and ‘negative’ if all were negative. CT testing was by in-house NAAT  
44  
45 on urine samples alone. Sexual history variables included sex between men (although this was  
46  
47 poorly completed and thus omitted from the analysis) and number of partners recorded in the  
48  
49 previous three months, as per the national guidelines at the time for taking a sexual history [9].  
50  
51  
52  
53  
54  
55  
56



1  
2  
3 All clinical and behavioural data were collected by the GUM, irrespective of the source of the  
4 diagnosis. GUM clinical policy includes routine recommendation of NG culture samples from  
5 the urethra and throat in all men with NG, plus a sample from the rectum in men who had sex  
6 with men (MSM). For females, NG culture samples are routinely recommended from the cervix,  
7 throat and rectum. NG cases were defined as patients who tested positive with NAAT, and  
8 adhered to the standards set out by Public Health England [1]. These policies were consistent  
9 irrespective of referral route. Patients not referred from the CSP were also tested with the GUM  
10 service in house Polymerase Chain Reaction (PCR) NAAT. Basic data (age, gender, postcode)  
11 were also available from the CSP for all individuals referred to GUM with a positive NG  
12 screening test who then failed to attend for treatment.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 Cases were assigned a study number and pseudoanonymised. Postcodes were linked to the lower  
30 super output area (LSOA) of residence (a statistical unit representing ~1,500 population) and  
31 then to area-level deprivation categories (English quintiles of deprivation, Index of Multiple  
32 Deprivation 2007[10]). Only 3% of cases resided in the least deprived two-fifths, so these cases  
33 were merged with the averagely deprived category. Firstly, the distribution of NG is displayed by  
34 Mosaic group, and compared to the distribution of city's households using chi square goodness  
35 of fit tests. Then, the demographic and clinical characteristics of CSP cases were compared with  
36 GUM cases using univariate chi square analysis, firstly for all cases and then for <25-year-olds  
37 (the target age range of the CSP). Cases with missing data were excluded from the analysis  
38 (ethnicity missing: 7; missing partner information: 14; symptoms and culture missing: 17. Cases  
39 with missing data were predominantly the 13 who were diagnosed by CSP but did not attend the  
40 GUM). Logistic regression (SPSS v20), using the source of the cases (CSP or GUM) as the  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 outcome, was used to assess independent relationships. The NHS Research Ethics Service  
4  
5 approved the study (08/H1002/70).  
6  
7  
8  
9  
10

## 11 12 13 **RESULTS**

14  
15 In total, 656 cases were identified , 131 (20%) of whom were diagnosed as a result of community  
16  
17 screening (114 primary cases who attended GUM for treatment, four contacts of primary cases  
18  
19 and thirteen who were diagnosed in the community but did not present to GUM for treatment).

20  
21 The community-diagnosed population, and their contacts, together inflated the GUM caseload by  
22  
23 23% (from 521 to 643, not including the 13 who did not present to GUM ). Allocation to  
24  
25 deprivation group and Mosaic group was possible for 576 (88%) of records. Since the proportion  
26  
27 of records with unknown deprivation category was relatively high, and because the probability of  
28  
29 missing data in this field is not random (the probability of missing postcode data is related to  
30  
31 deprivation and other risk indicators[11]), the missing values were coded as ‘deprivation  
32  
33 unknown’ and retained in the analysis.  
34  
35  
36  
37  
38  
39  
40

41 Table 1 shows the distribution of NG cases by Mosaic groups. The relatively affluent groups (B,  
42  
43 C, D) are at the top of the table (group A, a rural category, does not occur in the study city). The  
44  
45 distribution of NG does not follow the expected distribution based on the distribution of all  
46  
47 households in the study area ( $P < 0.001$  for all cases;  $P < 0.001$  for cases in people aged under 25  
48  
49 years). Inspection of the residuals reveals that cases of NG were under represented in the wealthy  
50  
51 groups B, C, D and F, and in the average group H. Cases were over-represented in ‘N-Young  
52  
53 people renting flats in high density social housing’ and ‘O-Families in low-rise social housing  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 with high levels of benefit need'. Group O itself is over-represented in the study area (27%)  
4  
5 compared to nationally (5%) [12]; in this study, 32% of all cases and 38% of cases in those aged  
6  
7 under 25 years of all NG cases resided in 'O'. Numbers of cases in each Mosaic group were too  
8  
9 low to compare CSP cases with GUM cases.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Distribution of cases of *Neisseria gonorrhoea* by Mosaic residential category, compared to the distribution of the general population of the city

| Mosaic category                                                   | All cases (n=578) |                             |                                    | Aged under 25y (n=340) |                         |                                    |
|-------------------------------------------------------------------|-------------------|-----------------------------|------------------------------------|------------------------|-------------------------|------------------------------------|
|                                                                   | N (%)             | Expected N (%) <sup>a</sup> | Standardised Residual <sup>b</sup> | N (%)                  | Expected N <sup>a</sup> | Standardised Residual <sup>c</sup> |
| B Residents of small and mid-sized towns with strong local roots  | 5 (0.86)          | 11.2 (1.94)                 | 7.69                               | 4 (1.2)                | 6.6 (1.94)              | 1.02                               |
| C Wealthy people living in the most sought after neighbourhoods   | 3 (0.52)          | 9.7 (1.67)                  | 14.96                              | 3 (0.9)                | 5.7 (1.67)              | 1.26                               |
| D Successful professionals living in suburban or semi-rural homes | 7 (1.2)           | 14.4 (2.49)                 | 7.82                               | 5 (1.5)                | 8.5 (2.49)              | 1.42                               |
| E Middle income families living in moderate suburban semis        | 55 (9.45)         | 61.8 (10.69)                | 0.84                               | 35 (10.3)              | 36.3 (10.69)            | 0.05                               |
| F Couples with young children in comfortable modern housing       | 6 (1.03)          | 11.9 (2.05)                 | 5.8                                | 2 (0.6)                | 7 (2.05)                | 3.54                               |
| G Young, well-educated city dwellers                              | 66 (11.34)        | 77.7 (13.45)                | 2.07                               | 33 (9.7)               | 45.7 (13.45)            | 3.55                               |
| H Couples and young singles in small modern starter homes         | 5 (0.86)          | 14.5 (2.5)                  | 18.05                              | 3 (0.9)                | 8.5 (2.5)               | 3.56                               |
| I Lower income workers in urban terraces in often diverse areas   | 66 (11.34)        | 60.2 (10.42)                | 0.51                               | 39 (11.5)              | 35.4 (10.42)            | 0.36                               |
| J Owner occupiers in older-style housing in ex-industrial areas   | 23 (3.95)         | 26.8 (4.63)                 | 0.63                               | 14 (4.1)               | 15.7 (4.63)             | 0.19                               |
| K Residents with sufficient incomes in right-to-buy social houses | 48 (8.25)         | 43.3 (7.49)                 | 0.46                               | 23 (6.8)               | 25.5 (7.49)             | 0.24                               |

|                                                                        |            |              |      |            |             |       |
|------------------------------------------------------------------------|------------|--------------|------|------------|-------------|-------|
| M Elderly people reliant on state support                              | 23 (3.95)  | 29.8 (5.16)  | 2.01 | 9 (2.6)    | 17.5 (5.16) | 4.16  |
| N Young people renting flats in high density social housing            | 76 (13.06) | 50.9 (8.8)   | 8.29 | 35 (10.3)  | 29.9 (8.8)  | 0.86  |
| O Families in low-rise social housing with high levels of benefit need | 188 (32.3) | 155.5 (26.9) | 5.62 | 128 (37.6) | 91.5 (26.9) | 14.59 |
| U Unclassified                                                         | 7 (1.2)    | 10.4 (1.8)   | 1.65 | 7 (2.1)    | 6.1 (1.8)   | 0.13  |

<sup>a</sup>Expected number of cases in each Mosaic category if cases were proportionally distributed to the general population distribution in the city where the clinic is located. Data taken from [12], which cites the Experian Mosaic Public Sector Tool.

<sup>b</sup>Chi square goodness of fit of observed distribution (cases of gonorrhoea) against expected (general population)=46.9; df=13, P<0.001

<sup>c</sup>Chi square goodness of fit of observed distribution (cases of gonorrhoea in those aged under 25 years) against expected (general population)=34.9, df =13, P=0.001

1  
2  
3  
4  
5  
6  
7  
8 Including all cases, whether attending the GUM for treatment or not (N=656), there were more  
9  
10 males diagnosed with NG than females (404 vs 252). The CSP predominantly contributed female  
11 cases (111, 85% of cases vs 27% female in GUM, chi square=148.4, P<0.001), leading to a 79%  
12 increase on the number of female cases that would have been detected in the absence of the CSP  
13 (from 141 to 252). The community cases and their contacts were labelled as 'CSP' to represent  
14 the additional cases (n=131). Cases labelled as 'GUM' (n=525) represent those diagnosed at  
15 GUM (i.e. 465 self-referrals to the open access clinic, 19 referrals from general practice and 41  
16 contacts). Similar numbers of females were identified by GUM and CSP (table 2). Not  
17 surprisingly, given the target age of the screening programme (those under 25years), the CSP  
18 group was younger (87% were aged under 25years vs 70% GUM, p=0.001). CSP females were  
19 more likely to reside in deprived areas compared to GUM females (p=0.014). Overall, only 43%  
20 of females had symptoms of NG. Not all cases found positive by NAAT were subsequently  
21 found to be positive by culture (overall, 10% of NAAT positive cases were not positive by  
22 culture, and this was higher for females, 18%, than males, 5%). Cases found positive by NAAT  
23 were treated as NG, as per national guidance [1]. In particular, females diagnosed NAAT  
24 positive for NG by the CSP (by Aptima Combo2) were more likely to be culture negative than  
25 were females identified NAAT positive by the in-house GUM PCR (25% vs 14% GUM,  
26 p=0.028). Of the nineteen male CSP cases who subsequently attended GUM, eight had no  
27 symptoms (42%). In contrast, only 12% of those identified through the GUM were symptomless  
28 (p<0.001). CT positivity was not significantly associated with setting in NG positive patients,  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 either for males (20.4% positive at GUM vs 31.6% at CSP;  $p=0.243$ ) or females (29.8% positive  
4  
5  
6 at GUM vs 41.4% positive at CSP,  $p=0.064$ ).  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 2. Demographic and clinical characteristics of cases of Neisseria gonorrhoea diagnosed in the genitourinary medicine (GUM) service compared with those identified as a result of the Chlamydia Screening Programme (CSP), by gender.

|                                     | Males |      |      |        | Females |      |      |        | Multivariate predictors of those aged <25years being diagnosed by CSP <sup>d</sup> |        |
|-------------------------------------|-------|------|------|--------|---------|------|------|--------|------------------------------------------------------------------------------------|--------|
|                                     | GUM   | CSP  | Chi  | P      | GUM     | CSP  | Chi  | P      | Adj OR (95% CI)                                                                    | P      |
| <i>Gender</i>                       |       |      |      |        |         |      |      |        |                                                                                    |        |
| Male                                | -     | -    | -    | -      | -       | -    | -    | -      | 1                                                                                  | <0.001 |
| Female                              | -     | -    | -    | -      | -       | -    | -    | -      | 9.5 (4.7—19.2)                                                                     |        |
| <i>Age<sup>a</sup> (N)</i>          | 384   | 20   |      |        | 141     | 111  |      |        |                                                                                    |        |
| <25 (%)                             | 50.3  | 85.0 | 9.2  | 0.002  | 69.5    | 86.5 | 10.1 | <0.001 | e-                                                                                 | -      |
| =>25 (%)                            | 49.7  | 15.0 |      |        | 30.5    | 13.5 |      |        |                                                                                    |        |
| <i>Ethnicity (N)</i>                | 379   | 20   |      |        | 141     | 109  |      |        |                                                                                    |        |
| Not white (%)                       | 9.8   | 10.0 | <0.1 | 1.000  | 14.9    | 10.1 | 1.3  | 0.34   | 0.9 (0.4-2.1)                                                                      | 0.866  |
| White (%)                           | 90.2  | 90.0 |      |        | 85.1    | 89.9 |      |        | 1                                                                                  |        |
| <i>IMD quintile<sup>b</sup> (N)</i> | 384   | 20   |      |        | 141     | 111  |      |        |                                                                                    |        |
| Average deprivation (%)             | 7.8   | 0    | 1.9  | 0.577  | 15.6    | 3.6  | 16.4 | <0.001 | 1                                                                                  | 0.037  |
| Fourth most deprived (%)            | 12.8  | 10.0 |      |        | 7.8     | 10.8 |      |        | 5.6 (1.4—21.8)                                                                     |        |
| Most deprived (%)                   | 67.4  | 75.0 |      |        | 69.5    | 66.7 |      |        | 5.3 (1.7—16.6)                                                                     |        |
| Unknown (%)                         | 12.0  | 15.0 |      |        | 7.1     | 18.9 |      |        | 5.6 (1.3—23.8)                                                                     |        |
| <i>No. Partners<sup>c</sup> (N)</i> | 384   | 19   |      |        | 141     | 98   |      |        |                                                                                    |        |
| One (%)                             | 21.6  | 31.6 | 1.9  | 0.384  | 63.8    | 54.1 | 3.6  | 0.165  | 1                                                                                  | 0.244  |
| Two (%)                             | 56.5  | 57.9 |      |        | 31.2    | 42.9 |      |        | 1.4 (0.8—2.6)                                                                      |        |
| Three or more (%)                   | 21.9  | 10.5 |      |        | 5       | 3.1  |      |        | 1.0 (0.3—3.1)                                                                      |        |
| <i>Symptoms (N)</i>                 | 381   | 19   |      |        | 141     | 98   |      |        |                                                                                    |        |
| No (%)                              | 11.8  | 42.1 | 14.5 | <0.001 | 53.2    | 63.3 | 2.4  | 0.121  | 1.9 (1.1—3.4)                                                                      | 0.021  |
| Yes (%)                             | 88.2  | 57.9 |      |        | 46.8    | 36.7 |      |        | 1                                                                                  |        |
| <i>Culture (N)</i>                  | 384   | 18   |      |        | 140     | 97   |      |        |                                                                                    |        |
| Negative (%)                        | 4.9   | 0    | 0.9  | 0.334  | 13.6    | 24.7 | 4.8  | 0.028  | 1                                                                                  | 0.370  |



|                      |      |      |     |       |      |      |     |       |               |       |
|----------------------|------|------|-----|-------|------|------|-----|-------|---------------|-------|
| Positive (%)         | 95.1 | 100  |     |       | 86.4 | 75.3 |     |       | 0.7 (0.3—1.5) |       |
| <i>CT status (N)</i> | 382  | 19   |     |       | 141  | 99   |     |       |               |       |
| Negative (%)         | 79.6 | 68.4 | 1.4 | 0.243 | 70.2 | 58.6 | 3.5 | 0.064 | 1             | 0.442 |
| Positive (%)         | 20.4 | 31.6 |     |       | 29.8 | 41.4 |     |       | 1.3 (0.7—2.2) |       |

CSP includes primary cases diagnosed in the community and 4 partners diagnosed as a result of contact tracing

GUM includes primary cases, self-referrals, referrals from general practice and partners of primary GUM cases

<sup>a</sup>Chi square analysis was repeated restricting to <25year-olds, and results were similar (see text).

<sup>b</sup>Least deprived and second least deprived quintiles were merged with the average deprivation category

<sup>c</sup>Number of partners in previous 3 months

<sup>d</sup>Logistic regression analysis with source of case as the outcome (CSP=1; GUM=0), restricted to those aged under 25years (n=404) who have complete data for partner number, symptoms and culture history (n=385). Predictor variables: gender, ethnicity, IMD, number of partners, CT status, symptoms (yes or no) and culture (negative or positive). AdjOR are adjusted odds ratios of being diagnosed by the CSP, with 95% confidence intervals.

<sup>e</sup>Age was excluded from multivariate analysis because analysis was restricted to <25years.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13 The CSP targets younger persons aged under 25years and therefore the univariate chi-square  
14 comparisons were repeated restricting to this younger age group in order to compare the profile  
15 of younger persons accessing the GUM with those using opportunistic screening. Results were  
16 similar to the all-age comparisons: there was no significant difference in the probability of being  
17 culture negative between the two settings (chi square=1.714, p=0.130); there was no significant  
18 association between CT positivity and setting (chi square=0.2, p=0.650); and men diagnosed in  
19 the community remained significantly less likely to have symptoms than younger men diagnosed  
20 in the GUM (chi square=4.996, p=0.037). Young females diagnosed in the community remained  
21 more likely to reside in deprived areas compared to young female GUM patients (chi-  
22 square=16.3, p=0.001). Findings from the univariate analysis were confirmed using multivariate  
23 analysis to find independently significant predictors of young people being detected by CSP  
24 rather than GUM (table 2). Analysis was restricted to this younger age group and confirmed that  
25 CSP cases were much more likely to be female (adjusted OR=9.9, 95% CI 4.9—19.8, P<0.001).  
26 After statistically controlling for the effect of gender, CSP cases had a two times higher odds  
27 (95% CI 1.1—3.6, P=0.021) of being symptomless and a five times higher odds of residing in the  
28 fourth or fifth most deprived quintiles compared to GUM cases (fourth: adj OR=5.4, 95%  
29 CI 1.4—20.9; fifth: adj OR=5.3, 95% CI 1.7—16.6; P=0.038).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

As a retrospective review of cases, there were no controls, limiting the conclusions from this study. Data recorded were variable in quality, and in particular there were only restricted data on those who were diagnosed by CSP but did not attend GUM. P-values of the univariate tests should be interpreted with caution since many tests were carried out, thereby increasing the risk of type I errors. The deprivation results and Mosaic groups should be interpreted with caution, since such area-level measures of deprivation may not represent the characteristics of individuals. An example of where area-level descriptors may be less helpful is the excess of cases of NG in those aged under 25 years (i.e. a young group) in areas typified by containing more older residents (the Mosaic group 'M-older people reliant on state support': table 1).

Despite these limitations, we have shown that use of NAATs can greatly increase the number of NG cases detected outside of clinic settings and have obtained epidemiological evidence of the demographic characteristics associated with these additional cases. This study confirms the association of NG with poverty that has been noted in the USA[13] and UK[7], and adds further insight by mapping to the 15 Mosaic groups. More than one third of cases came from a single Mosaic group, which represented deprived communities, and these were disproportionately represented compared to the study area as a whole. Community screening for NG contributed an additional 23% to the GUM caseload. Testing targeted was those aged under 25 years, and predominantly attracts women. Although not surprising, this has resulted in a doubling of NG infections detected in women in that age category, and these cases may have remained undetected in the absence of community screening.

1  
2  
3 Compared to the age-matched GUM women, the women detected by the CSP were qualitatively  
4 different, being yet more likely to reside in deprived areas, suggesting that community screening  
5 had accessed a yet more vulnerable population. CSP cases (especially males) were less likely to  
6 have symptoms, and therefore presumably less likely to present to clinical services. Although  
7 only statistically significant in the small number of males, we found a higher proportion of the  
8 community sample were culture negative. NG culture samples were obtained at the GUM clinic  
9 according to a strict policy based on gender and sexual history rather than route of referral and  
10 thus differences in culture results are unlikely to be the result of different testing practice. Our  
11 results support the notion that NG positive samples originating from community sites might  
12 more often represent low bacterial load or asymptomatic infection [14 15] although this  
13 conclusion is limited by the low sensitivity of bacterial culture for gonorrhoea.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 Since the data collection for this study was carried out, public policy on CT screening has been  
33 updated. The new Public Health Outcome Framework (PHOF) is used to monitor targets to  
34 increase the number of diagnoses (in the first instance, with the expectation that the target will be  
35 eventually to reduce prevalence)[16]. The major overarching aim of the PHOF is to reduce  
36 inequalities in health[17]. Although there are no specific NG targets, our data show that  
37 opportunistic CT/NG screening may contribute to reductions in health inequality by  
38 disproportionately benefitting lower SES groups. This is in direct contrast to other opportunistic  
39 screening programmes, which risk increasing such inequalities (e.g. for breast and cervical  
40 cancer[18]). The opportunity, within the CSP, to use low cost testing to detect low level,  
41 asymptomatic infections in a wider population has the potential to be an important influence on  
42 NG control and may contribute to the government's target to reduce health inequalities.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

## AUTHOR CONTRIBUTIONS

FA, HM and SS initiated the project. FA, LH-B, MW, KJ and JE-J collected the data. JE-J prepared the ethical review submission. PAC and HM analysed the data. JE-J, PAC and HM interpreted the results and compiled the first draft. All authors contributed to the revision of the manuscript.

## ACKNOWLEDGEMENTS

We would like to thank Jeannie Attard (Information Manager, GUM, Royal Liverpool and Broadgreen University Hospitals NHS Trust) for extracting the electronic records for this analysis.

## FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## COMPETING INTERESTS

JE-J and HM have received free testing kits from Gen Probe for previous small scale studies (using the *Trichomonas vaginalis* assay). None of the authors have a financial interest in the product or company, and none of the authors have received grants or fees from the company.

## REFERENCES

- 1 Health Protection Agency. Guidance for gonorrhoea testing in England and Wales.  
2  
3  
4  
5  
6  
7  
8  
9 [http://www.hpa.org.uk/webc/HPAwebFile/HPAweb\\_C/1267550166455](http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1267550166455), 2010.
- 10  
11 2 Public Health England. Chlamydia testing data for 15-24 year olds in England, April to June  
12  
13 2013: [http://www.chlamydia-screening.nhs.uk/ps/resources/data-tables/Q2%20-](http://www.chlamydia-screening.nhs.uk/ps/resources/data-tables/Q2%20-%202013%20CTAD%20Data%20Tables%20for%20publication%20Final.pdf)  
14  
15 [%202013%20CTAD%20Data%20Tables%20for%20publication%20Final.pdf](http://www.chlamydia-screening.nhs.uk/ps/resources/data-tables/Q2%20-%202013%20CTAD%20Data%20Tables%20for%20publication%20Final.pdf) (accessed  
16  
17 9 Jan 2014), 2013.
- 18  
19 3 Lavelle SJ, Mallinson H, Henning SJ, et al. Impact on gonorrhoea case reports through  
20  
21 concomitant/dual testing in a chlamydia screening population in Liverpool. Sex Transm  
22  
23 Infect 2007;**83**(7):593-4 doi: 10.1136/sti.2007.027870[published Online First: Epub  
24  
25 Date]].
- 26  
27 4 Skidmore S, Copley S, Cordwell D, et al. Positive nucleic acid amplification tests for Neisseria  
28  
29 gonorrhoeae in young people tested as part of the National Chlamydia Screening  
30  
31 Programme. Int J STD AIDS 2011;**22**(7):398-9 doi: 10.1258/ijsa.2011.010378[published  
32  
33 Online First: Epub Date]].
- 34  
35 5 Mahto M, Zia S, Ritchie D, et al. Diagnosis, management and prevalence estimation of  
36  
37 gonorrhoea: influences of Aptima Combo 2 assay with alternative target confirmation. Int  
38  
39 J STD AIDS 2009;**20**(5):315-9 doi: 10.1258/ijsa.2008.008410[published Online First:  
40  
41 Epub Date]].
- 42  
43 6 Risley CL, Ward H, Choudhury B, et al. Geographical and demographic clustering of  
44  
45 gonorrhoea in London. Sex Transm Infect 2007;**83**(6):481-7 doi:  
46  
47 10.1136/sti.2007.026021[published Online First: Epub Date]].
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 7 Hughes G, Nichols T, Peters L, et al. Repeat infection with gonorrhoea in Sheffield, UK: predictable and preventable? *Sex Transm Infect* 2013;**89**(1):38-44 doi: 10.1136/sextrans-2012-050495[published Online First: Epub Date]].
- 8 Mehta SD, Erbeding EJ, Zenilman JM, et al. Gonorrhoea reinfection in heterosexual STD clinic attendees: longitudinal analysis of risks for first reinfection. *Sex Transm Infect* 2003;**79**(2):124-28 doi: Doi 10.1136/Sti.79.2.124[published Online First: Epub Date]].
- 9 French P, Sexual History-Taking Working P, Clinical Effectiveness Group of the British Association for Sexual H, et al. BASHH 2006 National Guidelines--consultations requiring sexual history-taking. *Int J STD AIDS* 2007;**18**(1):17-22 doi: 10.1258/095646207779949989[published Online First: Epub Date]].
- 10 Office for National Statistics. Index of Multiple Deprivation (IMD) 2007. [http://data.gov.uk/dataset/index\\_of\\_multiple\\_deprivation\\_imd\\_2007](http://data.gov.uk/dataset/index_of_multiple_deprivation_imd_2007), 2007.
- 11 Dunn L, Henry J, Beard D. Social deprivation and adult head injury: a national study. *J Neurol Neurosurg Psychiatry* 2003;**74**(8):1060-4
- 12 Upton V, Agnew M, Bennett J, et al. Joint Strategic Needs Assessment (JSNA): statement of need 2011. <http://liverpool.gov.uk/D3BF7EE5-C08A-483A-909D-11586E1E478C/FinalDownload/DownloadId-1CF52DF971DC843A6A1DFDF4F5AB74EB/D3BF7EE5-C08A-483A-909D-11586E1E478C/media/100609/Liverpool-PCT-Current-and-Future-Health-and-Social-Care-Needs-2011.pdf> (accessed 8 Jan 2014): Liverpool PCT, 2011.
- 13 Krieger N, Waterman PD, Chen JT, et al. Monitoring socioeconomic inequalities in sexually transmitted infections, tuberculosis, and violence: Geocoding and choice of area-based socioeconomic measures - The public health disparities geocoding project (US). *Public*

- 1  
2  
3 Health Reports 2003;**118**(3):240-60 doi: Doi 10.1016/S0033-3549(04)50245-5[published  
4  
5 Online First: Epub Date]].  
6  
7  
8 14 Rogers SM, Miller HG, Miller WC, et al. NAAT-identified and self-reported gonorrhoea and  
9  
10 chlamydial infections: different at-risk population subgroups? Sex Transm Dis  
11  
12 2002;**29**(10):588-96  
13  
14  
15 15 Ross JD. Gonorrhoea: to screen or not to screen? Sex Transm Infect 2010;**86**(6):411-2 doi:  
16  
17 10.1136/sti.2010.042804[published Online First: Epub Date]].  
18  
19  
20 16 National Chlamydia Screening Programme. The NCSP: An Overview.  
21  
22 <http://www.chlamydia-screening.nhs.uk/ps/overview.asp> (accessed 8 Jan 2014); , 2013.  
23  
24  
25 17 Department of Health. Healthy lives, healthy people: Improving outcomes and supporting  
26  
27 transparency. 23 January 2012 (available at  
28  
29 [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/263658/29](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/263658/2901502_PHOF_Improving_Outcomes_PT1A_v1_1.pdf)  
30  
31 [01502\\_PHOF\\_Improving\\_Outcomes\\_PT1A\\_v1\\_1.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/263658/2901502_PHOF_Improving_Outcomes_PT1A_v1_1.pdf)) (accessed 8 Jan 2014), 2012  
32  
33  
34 18 Walsh B, Silles M, O'Neill C. The importance of socio-economic variables in cancer  
35  
36 screening participation: a comparison between population-based and opportunistic  
37  
38 screening in the EU-15. Health Policy 2011;**101**(3):269-76 doi:  
39  
40 10.1016/j.healthpol.2011.02.001[published Online First: Epub Date]].  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Title:  
4  
5

6 Comparison of patients diagnosed with gonorrhoea through community screening with those  
7  
8 self-presenting to the genito-urinary medicine clinic.  
9  
10

11  
12 Penny A. Cook<sup>1</sup>

13 John Evans-Jones<sup>2</sup>

14  
15 Harry Mallinson<sup>3</sup>

16  
17 Martyn Wood<sup>4</sup>

18  
19 Fath Alloba<sup>5</sup>

20  
21 Kathy Jones<sup>5</sup>

22  
23 Sara Strodbeck<sup>6</sup>

24  
25 Layla Hanna-Bashara<sup>7</sup>  
26  
27  
28  
29  
30  
31  
32

33  
34 <sup>1</sup>Correspondence: Penny A. Cook

35  
36 University of Salford

37  
38 School of Health Sciences

39  
40 Allerton Building

41  
42 Salford M6 6PU, UK

43  
44 p.a.cook@salford.ac.uk  
45  
46  
47  
48  
49

50  
51 <sup>2</sup>John Evans-Jones

52  
53 Countess of Chester Hospital NHS Foundation Trust

54  
55 Countess of Chester Health Park  
56  
57  
58  
59  
60

1  
2  
3 Liverpool Road  
4  
5  
6 Chester CH2 1UL  
7  
8  
9

10 <sup>3</sup>Harry Mallinson  
11  
12 Retired Consultant Clinical Scientist  
13  
14 Microbiology Laboratory  
15  
16  
17 Aintree University Hospitals NHS Foundation Trust  
18  
19  
20 hm@haytor1.plus.com  
21  
22  
23

24 <sup>4</sup>Martyn Wood  
25  
26  
27 Centre for Sexual Health and Contraception  
28  
29 Mid-Cheshire Hospitals NHS Foundation Trust  
30  
31  
32 Middlewich Road  
33  
34 Crewe  
35  
36 Cheshire  
37  
38  
39 CW1 4QJ  
40  
41  
42

43 <sup>5</sup>Fath Alloba, Kathy Jones  
44  
45  
46 Royal Liverpool and Broadgreen University Hospitals NHS Trust  
47  
48 Royal Liverpool University Hospital  
49  
50 Prescot Street  
51  
52  
53 Liverpool  
54  
55  
56 L7 8XP  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 <sup>6</sup>Sara Strodbeck  
7

8 Liverpool Community Health NHS Trust  
9

10 Citrus House  
11

12 40-46 Dale Street  
13

14 Liverpool L2 5SF  
15  
16  
17  
18  
19

20 <sup>7</sup>Layla Hanna-Bashara  
21

22 Department of Dermatology  
23

24 Royal Liverpool and Broadgreen University Hospitals NHS Trust  
25

26 Broadgreen Hospital  
27

28 Kent lodge  
29

30 Thomas drive  
31

32 Liverpool L14 3LB  
33  
34  
35  
36  
37  
38

39 Running head: Testing for gonorrhoea in the community  
40  
41  
42

43 *Key words: Neisseria gonorrhoeae, Mass Screening, Residence Characteristics,*  
44

45  
46 *Community Health Services, socioeconomic status*  
47  
48  
49

50  
51 Word Count: 2381  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** To compare the **clinical, socioeconomic and demographic** characteristics of individuals diagnosed with Neisseria gonorrhoea (NG) in the community using concomitant a Nucleic Acid Amplification Test (NAAT, AptimaCombo2) testing as part of the (community-based) United Kingdom Chlamydia Screening Programme (CSP), with those diagnosed in hospital-based Genitourinary Medicine (GUM) services.

**Design:** A retrospective case note review of all 643 patients treated for NG at a GUM in north west England (01/2007—04/2009).

**Participants:** All 643 treated for NG (including CSP cases, since all cases were referred to GUM for treatment). Limited data were available for 13 CSP cases who failed to attend GUM.

**Primary outcome measure:** Whether the case was detected in the community or GUM.

Predictors were demographics (age, gender, postcode for deprivation analysis), sexual history (e.g. number of partners) and clinical factors (e.g. culture positivity).

**Results:** **131 cases were diagnosed by CSP (13 of whom did not attend GUM). A further 4 cases were contacts of these. The GUM caseload was thus inflated by 23% (from 521 to 643).**

Community cases were overwhelmingly female (85% vs 27% in GUM,  $P < 0.001$ ) and younger (87% females were  $< 25$ y vs 70% GUM females,  $p = 0.001$ ). Logistic regression analysis restricted to the target age of the CSP ( $< 25$ y) revealed that CSP cases, compared to GUM cases, were more likely to reside in deprived areas (adjusted OR = 5.6, 95%CI 1.4—21.8 and 5.3, CI 1.7—16.6 for the most and second most deprived group respectively, compared to the averagely deprived group,  $p = 0.037$ ) and be asymptomatic (adjOR=1.9, CI 1.1—3.4, 0.02).

**Conclusion**

1  
2  
3 Community screening for NG led to a 79% increase in the number of infections detected in  
4  
5 women aged <25y. Screening is targeted at young people, and tends to disproportionately attract  
6  
7 young women, a group under-represented at GUM. Screening also contributed further to case  
8  
9 detection in deprived areas.  
10  
11  
12  
13

## 14 15 **ARTICLE SUMMARY**

### 16 17 18 **Strengths and limitations of this study**

- 19 • Little attention has been paid to the possibility that screening programmes improve  
20 diagnosis in populations that would not traditionally attend GUM. This study fills a gap  
21 in knowledge about the socioeconomic status of those identified in the different settings.  
22  
23
- 24 • NG cases were over-represented in particular relatively deprived areas of the study area,  
25 as shown by geodemographic profiling (the Mosaic tool).  
26  
27
- 28 • Community screening for NG contributed extra female cases, asymptomatic male cases  
29 and cases from relatively more deprived areas, which may have otherwise remained  
30 undetected.  
31  
32
- 33 • As a retrospective review of cases, there were no controls, limiting the conclusions from  
34 this study.  
35  
36
- 37 • The deprivation results and Mosaic groups should be interpreted with caution, since such  
38 area-level measures of deprivation may not represent the characteristics of individuals.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Nucleic acid amplification tests (NAATs) have greater sensitivity than culture and are now widely used to diagnose sexually transmitted infections (STIs), including *Neisseria gonorrhoeae* (NG) using non-invasive and easily transportable samples. However, in low prevalence populations where an NG NAAT might not display a positive predictive value exceeding 90%, positive samples are now recommended to be subjected to confirmatory testing.[1]

The UK national Chlamydia Screening Programme (CSP) is an opportunistic screening programme which uses NAATs for *Chlamydia trachomatis* (CT). The programme is targeted at all young people aged under 25 years (although tends to be predominantly taken up by women[2]), and based in community settings such as pharmacies, community contraception clinics, primary care, schools and colleges. Concomitant NAAT screening for both CT and NG (Aptima Combo 2 assay, Gen-Probe Inc, San Diego, CA, USA) using either self-taken or clinician samples was introduced into the study area CSP in 2004 at the same cost as a CT test alone. Cases of NG identified are subsequently referred to the specialist Genitourinary Medicine (GUM) service for parenteral treatment, specialist partner notification and antibiotic sensitivity testing. The overall detection of NG has increased in areas where such an approach has been implemented.[3-5]

Previous studies of NG epidemiology have been based on GUM clinic populations [6-8] and therefore less is known about the characteristics of cases that are detected outside GUM. Such analysis that does exist confirms the characteristics that would be expected based on the target and settings of the screening programme (i.e. young women)[5]. Little attention has been paid to

1  
2  
3 the possibility that screening programmes improve diagnosis in populations that would not  
4 traditionally attend GUM. This study compares the demographic and clinical profile of NG cases  
5 detected by the CSP with that of a GUM clinic population with a specific aim to fill the gap in  
6 knowledge about the socioeconomic status of those identified in the different settings.  
7  
8  
9  
10  
11  
12  
13

## 14 15 16 METHODS

17 A cross-sectional retrospective case note review was completed of all cases of complicated and  
18 uncomplicated NG attending a GUM service between 01/01/07 and 31/03/09, identified from  
19 GUM clinic records (using the Sexual Health and HIV Activity Property Type—SHHAPT—  
20 surveillance report codes). The GUM is located in a large city, adjacent to some of the most  
21 deprived areas in England. The referral route was recorded as follows: diagnosed in the open-  
22 access GUM clinic; referred from the CSP; a contact of an NG case; referred from general  
23 practice. Demographic data collected included: postcode (to allow allocation of an area-based  
24 deprivation measure and use of a postcode classification tool, Mosaic, that uses over 400 data  
25 indicators to classify all UK citizens into fifteen population types, 'Mosaic groups'), gender, age  
26 (either <25years, the target age for the CSP, or ≥25years) and ethnicity. Clinical data were:  
27 symptoms of NG; NG culture results; CT test result. Clinic policy was for NG culture samples to  
28 be recommended as a minimum of one sample per NG from up to four anatomical sites in total:  
29 pharynx, rectum, cervix (women only), and urethra. Culture result was recorded as 'positive' if  
30 one or more was positive, and 'negative' if all were negative. CT testing was by in-house NAAT  
31 on urine samples alone. Sexual history variables included sex between men (although this was  
32 poorly completed and thus omitted from the analysis) and number of partners recorded in the  
33 previous three months, as per the national guidelines at the time for taking a sexual history [9].  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3 All clinical and behavioural data were collected by the GUM, irrespective of the source of the  
4 diagnosis. GUM clinical policy includes routine recommendation of NG culture samples from  
5 the urethra and throat in all men with NG, plus a sample from the rectum in men who had sex  
6 with men (MSM). For females, NG culture samples are routinely recommended from the cervix,  
7 throat and rectum. NG cases were defined as patients who tested positive with NAAT, and  
8 adhered to the standards set out by Public Health England [1]. These policies were consistent  
9 irrespective of referral route. Patients not referred from the CSP were also tested with the GUM  
10 service in house Polymerase Chain Reaction (PCR) NAAT. Basic data (age, gender, postcode)  
11 were also available from the CSP for all individuals referred to GUM with a positive NG  
12 screening test who then failed to attend for treatment.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 Cases were assigned a study number and pseudoanonymised. Postcodes were linked to the lower  
30 super output area (LSOA) of residence (a statistical unit representing ~1,500 population) and  
31 then to area-level deprivation categories (English quintiles of deprivation, Index of Multiple  
32 Deprivation 2007[10]). Only 3% of cases resided in the least deprived two-fifths, so these cases  
33 were merged with the averagely deprived category. Firstly, the distribution of NG is displayed by  
34 Mosaic group, and compared to the distribution of city's households using chi square goodness  
35 of fit tests. Then, the demographic and clinical characteristics of CSP cases were compared with  
36 GUM cases using univariate chi square analysis, firstly for all cases and then for <25-year-olds  
37 (the target age range of the CSP). Cases with missing data were excluded from the analysis  
38 (ethnicity missing: 7; missing partner information: 14; symptoms and culture missing: 17. Cases  
39 with missing data were predominantly the 13 who were diagnosed by CSP but did not attend the  
40 GUM). Logistic regression (SPSS v20), using the source of the cases (CSP or GUM) as the  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 outcome, was used to assess independent relationships. The NHS Research Ethics Service  
4  
5 approved the study (08/H1002/70).  
6  
7  
8  
9  
10

## 11 12 13 RESULTS

14  
15 In total, 656 cases were identified , 131 (20%) of whom were diagnosed as a result of community  
16  
17 screening (114 primary cases who attended GUM for treatment, four contacts of primary cases  
18  
19 and thirteen who were diagnosed in the community but did not present to GUM for treatment).

20  
21 The community-diagnosed population, and their contacts, together inflated the GUM caseload by  
22  
23 23% (from 521 to 643, not including the 13 who did not present to GUM ). Allocation to  
24  
25 deprivation group and Mosaic group was possible for 576 (88%) of records. Since the proportion  
26  
27 of records with unknown deprivation category was relatively high, and because the probability of  
28  
29 missing data in this field is not random (the probability of missing postcode data is related to  
30  
31 deprivation and other risk indicators[11]), the missing values were coded as ‘deprivation  
32  
33 unknown’ and retained in the analysis.  
34  
35  
36  
37  
38  
39  
40

41  
42 Table 1 shows the distribution of NG cases by Mosaic groups. The relatively affluent groups (B,  
43  
44 C, D) are at the top of the table (group A, a rural category, does not occur in the study city). The  
45  
46 distribution of NG does not follow the expected distribution based on the distribution of all  
47  
48 households in the study area ( $P < 0.001$  for all cases;  $P < 0.001$  for cases in people aged under 25  
49  
50 years). Inspection of the residuals reveals that cases of NG were under represented in the wealthy  
51  
52 groups B, C, D and F, and in the average group H. Cases were over-represented in ‘N-Young  
53  
54 people renting flats in high density social housing’ and ‘O-Families in low-rise social housing  
55  
56  
57  
58  
59  
60

1  
2  
3 with high levels of benefit need'. Group O itself is over-represented in the study area (27%)  
4  
5 compared to nationally (5%) [12]; in this study, 32% of all cases and 38% of cases in those aged  
6  
7 under 25 years of all NG cases resided in 'O'. Numbers of cases in each Mosaic group were too  
8  
9 low to compare CSP cases with GUM cases.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Distribution of cases of *Neisseria gonorrhoea* by Mosaic residential category, compared to the distribution of the general population of the city

| Mosaic category                                                   | All cases (n=578) |                             |                                    | Aged under 25y (n=340) |                         |                                    |
|-------------------------------------------------------------------|-------------------|-----------------------------|------------------------------------|------------------------|-------------------------|------------------------------------|
|                                                                   | N (%)             | Expected N (%) <sup>a</sup> | Standardised Residual <sup>b</sup> | N (%)                  | Expected N <sup>a</sup> | Standardised Residual <sup>c</sup> |
| B Residents of small and mid-sized towns with strong local roots  | 5 (0.86)          | 11.2 (1.94)                 | 7.69                               | 4 (1.2)                | 6.6 (1.94)              | 1.02                               |
| C Wealthy people living in the most sought after neighbourhoods   | 3 (0.52)          | 9.7 (1.67)                  | 14.96                              | 3 (0.9)                | 5.7 (1.67)              | 1.26                               |
| D Successful professionals living in suburban or semi-rural homes | 7 (1.2)           | 14.4 (2.49)                 | 7.82                               | 5 (1.5)                | 8.5 (2.49)              | 1.42                               |
| E Middle income families living in moderate suburban semis        | 55 (9.45)         | 61.8 (10.69)                | 0.84                               | 35 (10.3)              | 36.3 (10.69)            | 0.05                               |
| F Couples with young children in comfortable modern housing       | 6 (1.03)          | 11.9 (2.05)                 | 5.8                                | 2 (0.6)                | 7 (2.05)                | 3.54                               |
| G Young, well-educated city dwellers                              | 66 (11.34)        | 77.7 (13.45)                | 2.07                               | 33 (9.7)               | 45.7 (13.45)            | 3.55                               |
| H Couples and young singles in small modern starter homes         | 5 (0.86)          | 14.5 (2.5)                  | 18.05                              | 3 (0.9)                | 8.5 (2.5)               | 3.56                               |
| I Lower income workers in urban terraces in often diverse areas   | 66 (11.34)        | 60.2 (10.42)                | 0.51                               | 39 (11.5)              | 35.4 (10.42)            | 0.36                               |
| J Owner occupiers in older-style housing in ex-industrial areas   | 23 (3.95)         | 26.8 (4.63)                 | 0.63                               | 14 (4.1)               | 15.7 (4.63)             | 0.19                               |
| K Residents with sufficient incomes in right-to-buy social houses | 48 (8.25)         | 43.3 (7.49)                 | 0.46                               | 23 (6.8)               | 25.5 (7.49)             | 0.24                               |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

|                                                                        |            |              |      |            |             |       |
|------------------------------------------------------------------------|------------|--------------|------|------------|-------------|-------|
| M Elderly people reliant on state support                              | 23 (3.95)  | 29.8 (5.16)  | 2.01 | 9 (2.6)    | 17.5 (5.16) | 4.16  |
| N Young people renting flats in high density social housing            | 76 (13.06) | 50.9 (8.8)   | 8.29 | 35 (10.3)  | 29.9 (8.8)  | 0.86  |
| O Families in low-rise social housing with high levels of benefit need | 188 (32.3) | 155.5 (26.9) | 5.62 | 128 (37.6) | 91.5 (26.9) | 14.59 |
| U Unclassified                                                         | 7 (1.2)    | 10.4 (1.8)   | 1.65 | 7 (2.1)    | 6.1 (1.8)   | 0.13  |

<sup>a</sup>Expected number of cases in each Mosaic category if cases were proportionally distributed to the general population distribution in the city where the clinic is located. Data taken from [12], which cites the Experian Mosaic Public Sector Tool.

<sup>b</sup>Chi square goodness of fit of observed distribution (cases of gonorrhoea) against expected (general population)=46.9; df=13, P<0.001

<sup>c</sup>Chi square goodness of fit of observed distribution (cases of gonorrhoea in those aged under 25 years) against expected (general population)=34.9, df =13, P=0.001

1  
2  
3  
4  
5  
6  
7  
8 Including all cases, whether attending the GUM for treatment or not (N=656), there were more  
9  
10 males diagnosed with NG than females (404 vs 252). The CSP predominantly contributed female  
11 cases (111, 85% of cases vs 27% female in GUM, chi square=148.4, P<0.001), leading to a 79%  
12 increase on the number of female cases that would have been detected in the absence of the CSP  
13 (from 141 to 252). The community cases and their contacts were labelled as 'CSP' to represent  
14 the additional cases (n=131). Cases labelled as 'GUM' (n=525) represent those diagnosed at  
15 GUM (i.e. 465 self-referrals to the open access clinic, 19 referrals from general practice and 41  
16 contacts). Similar numbers of females were identified by GUM and CSP (table 2). Not  
17 surprisingly, given the target age of the screening programme (those under 25years), the CSP  
18 group was younger (87% were aged under 25years vs 70% GUM, p=0.001). CSP females were  
19 more likely to reside in deprived areas compared to GUM females (p=0.014). Overall, only 43%  
20 of females had symptoms of NG. Not all cases found positive by NAAT were subsequently  
21 found to be positive by culture (overall, 10% of NAAT positive cases were not positive by  
22 culture, and this was higher for females, 18%, than males, 5%). Cases found positive by NAAT  
23 were treated as NG, as per national guidance [1]. In particular, females diagnosed NAAT  
24 positive for NG by the CSP (by Aptima Combo2) were more likely to be culture negative than  
25 were females identified NAAT positive by the in-house GUM PCR (25% vs 14% GUM,  
26 p=0.028). Of the nineteen male CSP cases who subsequently attended GUM, eight had no  
27 symptoms (42%). In contrast, only 12% of those identified through the GUM were symptomless  
28 (p<0.001). CT positivity was not significantly associated with setting in NG positive patients,  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

either for males (20.4% positive at GUM vs 31.6% at CSP;  $p=0.243$ ) or females (29.8% positive at GUM vs 41.4% positive at CSP,  $p=0.064$ ).

For peer review only

Table 2. Demographic and clinical characteristics of cases of *Neisseria gonorrhoea* diagnosed in the genitourinary medicine (GUM) service compared with those identified as a result of the Chlamydia Screening Programme (CSP), by gender.

|                                     | Males |      |      |        | Females |      |      |        | Multivariate predictors of those aged <25years being diagnosed by CSP <sup>d</sup> |        |
|-------------------------------------|-------|------|------|--------|---------|------|------|--------|------------------------------------------------------------------------------------|--------|
|                                     | GUM   | CSP  | Chi  | P      | GUM     | CSP  | Chi  | P      | Adj OR (95% CI)                                                                    | P      |
| <i>Gender</i>                       |       |      |      |        |         |      |      |        |                                                                                    |        |
| Male                                | -     | -    | -    | -      | -       | -    | -    | -      | 1                                                                                  | <0.001 |
| Female                              | -     | -    | -    | -      | -       | -    | -    | -      | 9.5 (4.7—19.2)                                                                     |        |
| <i>Age<sup>a</sup> (N)</i>          | 384   | 20   |      |        | 141     | 111  |      |        |                                                                                    |        |
| <25 (%)                             | 50.3  | 85.0 | 9.2  | 0.002  | 69.5    | 86.5 | 10.1 | <0.001 | e-                                                                                 | -      |
| =>25 (%)                            | 49.7  | 15.0 |      |        | 30.5    | 13.5 |      |        |                                                                                    |        |
| <i>Ethnicity (N)</i>                | 379   | 20   |      |        | 141     | 109  |      |        |                                                                                    |        |
| Not white (%)                       | 9.8   | 10.0 | <0.1 | 1.000  | 14.9    | 10.1 | 1.3  | 0.34   | 0.9 (0.4-2.1)                                                                      | 0.866  |
| White (%)                           | 90.2  | 90.0 |      |        | 85.1    | 89.9 |      |        | 1                                                                                  |        |
| <i>IMD quintile<sup>b</sup> (N)</i> | 384   | 20   |      |        | 141     | 111  |      |        |                                                                                    |        |
| Average deprivation (%)             | 7.8   | 0    | 1.9  | 0.577  | 15.6    | 3.6  | 16.4 | <0.001 | 1                                                                                  | 0.037  |
| Fourth most deprived (%)            | 12.8  | 10.0 |      |        | 7.8     | 10.8 |      |        | 5.6 (1.4—21.8)                                                                     |        |
| Most deprived (%)                   | 67.4  | 75.0 |      |        | 69.5    | 66.7 |      |        | 5.3 (1.7—16.6)                                                                     |        |
| Unknown (%)                         | 12.0  | 15.0 |      |        | 7.1     | 18.9 |      |        | 5.6 (1.3—23.8)                                                                     |        |
| <i>No. Partners<sup>c</sup> (N)</i> | 384   | 19   |      |        | 141     | 98   |      |        |                                                                                    |        |
| One (%)                             | 21.6  | 31.6 | 1.9  | 0.384  | 63.8    | 54.1 | 3.6  | 0.165  | 1                                                                                  | 0.244  |
| Two (%)                             | 56.5  | 57.9 |      |        | 31.2    | 42.9 |      |        | 1.4 (0.8—2.6)                                                                      |        |
| Three or more (%)                   | 21.9  | 10.5 |      |        | 5       | 3.1  |      |        | 1.0 (0.3—3.1)                                                                      |        |
| <i>Symptoms (N)</i>                 | 381   | 19   |      |        | 141     | 98   |      |        |                                                                                    |        |
| No (%)                              | 11.8  | 42.1 | 14.5 | <0.001 | 53.2    | 63.3 | 2.4  | 0.121  | 1.9 (1.1—3.4)                                                                      | 0.021  |
| Yes (%)                             | 88.2  | 57.9 |      |        | 46.8    | 36.7 |      |        | 1                                                                                  |        |
| <i>Culture (N)</i>                  | 384   | 18   |      |        | 140     | 97   |      |        |                                                                                    |        |
| Negative (%)                        | 4.9   | 0    | 0.9  | 0.334  | 13.6    | 24.7 | 4.8  | 0.028  | 1                                                                                  | 0.370  |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

|                      |            |           |     |       |            |           |     |       |               |       |
|----------------------|------------|-----------|-----|-------|------------|-----------|-----|-------|---------------|-------|
| Positive (%)         | 95.1       | 100       |     |       | 86.4       | 75.3      |     |       | 0.7 (0.3—1.5) |       |
| <i>CT status (N)</i> | <i>382</i> | <i>19</i> |     |       | <i>141</i> | <i>99</i> |     |       |               |       |
| Negative (%)         | 79.6       | 68.4      | 1.4 | 0.243 | 70.2       | 58.6      | 3.5 | 0.064 | 1             | 0.442 |
| Positive (%)         | 20.4       | 31.6      |     |       | 29.8       | 41.4      |     |       | 1.3 (0.7—2.2) |       |

CSP includes primary cases diagnosed in the community and 4 partners diagnosed as a result of contact tracing  
 GUM includes primary cases, self-referrals, referrals from general practice and partners of primary GUM cases  
<sup>a</sup>Chi square analysis was repeated restricting to <25year-olds, and results were similar (see text).  
<sup>b</sup>Least deprived and second least deprived quintiles were merged with the average deprivation category  
<sup>c</sup>Number of partners in previous 3 months  
<sup>d</sup>Logistic regression analysis with source of case as the outcome (CSP=1; GUM=0), restricted to those aged under 25years (n=404) who have complete data for partner number, symptoms and culture history (n=385). **Predictor variables: gender, ethnicity, IMD, number of partners, CT status, symptoms (yes or no) and culture (negative or positive).** AdjOR are adjusted odds ratios of being diagnosed by the CSP, with 95% confidence intervals.  
<sup>e</sup>Age was excluded from multivariate analysis because analysis was restricted to <25years.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13 The CSP targets younger persons aged under 25years and therefore the univariate chi-square  
14 comparisons were repeated restricting to this younger age group in order to compare the profile  
15 of younger persons accessing the GUM with those using opportunistic screening. Results were  
16 similar to the all-age comparisons: there was no significant difference in the probability of being  
17 culture negative between the two settings (chi square=1.714, p=0.130); there was no significant  
18 association between CT positivity and setting (chi square=0.2, p=0.650); and men diagnosed in  
19 the community remained significantly less likely to have symptoms than younger men diagnosed  
20 in the GUM (chi square=4.996, p=0.037). Young females diagnosed in the community remained  
21 more likely to reside in deprived areas compared to young female GUM patients (chi-  
22 square=16.3, p=0.001). Findings from the univariate analysis were confirmed using multivariate  
23 analysis to find independently significant predictors of young people being detected by CSP  
24 rather than GUM (table 2). Analysis was restricted to this younger age group and confirmed that  
25 CSP cases were much more likely to be female (adjusted OR=9.9, 95% CI 4.9—19.8, P<0.001).  
26 After statistically controlling for the effect of gender, CSP cases had a two times higher odds  
27 (95% CI 1.1—3.6, P=0.021) of being symptomless and a five times higher odds of residing in the  
28 fourth or fifth most deprived quintiles compared to GUM cases (fourth: adj OR=5.4, 95%  
29 CI 1.4—20.9; fifth: adj OR=5.3, 95% CI 1.7—16.6; P=0.038).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

As a retrospective review of cases, there were no controls, limiting the conclusions from this study. Data recorded were variable in quality, and in particular there were only restricted data on those who were diagnosed by CSP but did not attend GUM. P-values of the univariate tests should be interpreted with caution since many tests were carried out, thereby increasing the risk of type I errors. The deprivation results and Mosaic groups should be interpreted with caution, since such area-level measures of deprivation may not represent the characteristics of individuals. An example of where area-level descriptors may be less helpful is the excess of cases of NG in those aged under 25 years (i.e. a young group) in areas typified by containing more older residents (the Mosaic group 'M-older people reliant on state support': table 1).

Despite these limitations, we have shown that use of NAATs can greatly increase the number of NG cases detected outside of clinic settings and have obtained epidemiological evidence of the demographic characteristics associated with these additional cases. This study confirms the association of NG with poverty that has been noted in the USA[13] and UK[7], and adds further insight by mapping to the 15 Mosaic groups. More than one third of cases came from a single Mosaic group, which represented deprived communities, and these were disproportionately represented compared to the study area as a whole. Community screening for NG contributed an additional 23% to the GUM caseload. Testing targeted was those aged under 25 years, and predominantly attracts women. Although not surprising, this has resulted in a doubling of NG infections detected in women in that age category, and these cases may have remained undetected in the absence of community screening.

1  
2  
3 Compared to the age-matched GUM women, the women detected by the CSP were qualitatively  
4 different, being **yet** more likely to reside in deprived areas, suggesting that community screening  
5 had accessed a **yet** more vulnerable population. CSP cases (especially males) were less likely to  
6 have symptoms, and therefore presumably less likely to present to clinical services. Although  
7 only **statistically** significant in the small number of males, we found a higher proportion of the  
8 community sample were culture negative. NG culture samples were obtained at the GUM clinic  
9 according to a strict policy based on gender and sexual history rather than route of referral and  
10 thus differences in culture results are unlikely to be the result of different testing practice. Our  
11 results support the notion that NG positive samples originating from community sites might  
12 more often represent low bacterial load or asymptomatic infection [14 15] **although this**  
13 **conclusion is limited by the low sensitivity of bacterial culture for gonorrhoea.**  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 **Since the data collection for this study was carried out, public policy on CT screening has been**  
33 **updated. The new Public Health Outcome Framework (PHOF) is used to monitor targets to**  
34 **increase the number of diagnoses (in the first instance, with the expectation that the target will be**  
35 **eventually to reduce prevalence)[16]. The major overarching aim of the PHOF is to reduce**  
36 **inequalities in health[17]. Although there are no specific NG targets, our data show that**  
37 **opportunistic CT/NG screening may contribute to reductions in health inequality by**  
38 **disproportionately benefitting lower SES groups. This is in direct contrast to other opportunistic**  
39 **screening programmes, which risk increasing such inequalities (e.g. for breast and cervical**  
40 **cancer[18]). The opportunity, within the CSP, to use low cost testing to detect low level,**  
41 **asymptomatic infections in a wider population has the potential to be an important influence on**  
42 **NG control and may contribute to the government's target to reduce health inequalities.**  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## AUTHOR CONTRIBUTIONS

FA, HM and SS initiated the project. FA, LH-B, MW, KJ and JE-J collected the data. JE-J prepared the ethical review submission. PAC and HM analysed the data. JE-J, PAC and HM interpreted the results and compiled the first draft. All authors contributed to the revision of the manuscript.

## ACKNOWLEDGEMENTS

We would like to thank Jeannie Attard (Information Manager, GUM, Royal Liverpool and Broadgreen University Hospitals NHS Trust) for extracting the electronic records for this analysis.

## FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

## COMPETING INTERESTS

JE-J and HM have received free testing kits from Gen Probe for previous small scale studies (using the *Trichomonas vaginalis* assay). None of the authors have a financial interest in the product or company, and none of the authors have received grants or fees from the company.

## REFERENCES

- 1 Health Protection Agency. Guidance for gonorrhoea testing in England and Wales.  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  

1 Health Protection Agency. Guidance for gonorrhoea testing in England and Wales.  
[http://www.hpa.org.uk/webc/HPAwebFile/HPAweb\\_C/1267550166455](http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1267550166455), 2010.
- 2 Public Health England. Chlamydia testing data for 15-24 year olds in England, April to June  
2013: <http://www.chlamydia-screening.nhs.uk/ps/resources/data-tables/Q2%20-%202013%20CTAD%20Data%20Tables%20for%20publication%20Final.pdf> (accessed  
9 Jan 2014), 2013.
- 3 Lavelle SJ, Mallinson H, Henning SJ, et al. Impact on gonorrhoea case reports through  
concomitant/dual testing in a chlamydia screening population in Liverpool. *Sex Transm  
Infect* 2007;**83**(7):593-4 doi: 10.1136/sti.2007.027870[published Online First: Epub  
Date]].
- 4 Skidmore S, Copley S, Cordwell D, et al. Positive nucleic acid amplification tests for *Neisseria  
gonorrhoeae* in young people tested as part of the National Chlamydia Screening  
Programme. *Int J STD AIDS* 2011;**22**(7):398-9 doi: 10.1258/ijsa.2011.010378[published  
Online First: Epub Date]].
- 5 Mahto M, Zia S, Ritchie D, et al. Diagnosis, management and prevalence estimation of  
gonorrhoea: influences of Aptima Combo 2 assay with alternative target confirmation. *Int  
J STD AIDS* 2009;**20**(5):315-9 doi: 10.1258/ijsa.2008.008410[published Online First:  
Epub Date]].
- 6 Risley CL, Ward H, Choudhury B, et al. Geographical and demographic clustering of  
gonorrhoea in London. *Sex Transm Infect* 2007;**83**(6):481-7 doi:  
10.1136/sti.2007.026021[published Online First: Epub Date]].

- 1  
2  
3 7 Hughes G, Nichols T, Peters L, et al. Repeat infection with gonorrhoea in Sheffield, UK:  
4  
5 predictable and preventable? *Sex Transm Infect* 2013;**89**(1):38-44 doi: 10.1136/sextrans-  
6  
7 2012-050495[published Online First: Epub Date]].  
8  
9  
10 8 Mehta SD, Erbeling EJ, Zenilman JM, et al. Gonorrhoea reinfection in heterosexual STD  
11  
12 clinic attendees: longitudinal analysis of risks for first reinfection. *Sex Transm Infect*  
13  
14 2003;**79**(2):124-28 doi: Doi 10.1136/Sti.79.2.124[published Online First: Epub Date]].  
15  
16  
17 9 French P, Sexual History-Taking Working P, Clinical Effectiveness Group of the British  
18  
19 Association for Sexual H, et al. BASHH 2006 National Guidelines--consultations  
20  
21 requiring sexual history-taking. *Int J STD AIDS* 2007;**18**(1):17-22 doi:  
22  
23 10.1258/095646207779949989[published Online First: Epub Date]].  
24  
25  
26 10 Office for National Statistics. Index of Multiple Deprivation (IMD) 2007.  
27  
28 [http://data.gov.uk/dataset/index\\_of\\_multiple\\_deprivation\\_imd\\_2007](http://data.gov.uk/dataset/index_of_multiple_deprivation_imd_2007), 2007.  
29  
30  
31 11 Dunn L, Henry J, Beard D. Social deprivation and adult head injury: a national study. *J*  
32  
33 *Neurol Neurosurg Psychiatry* 2003;**74**(8):1060-4  
34  
35  
36 12 Upton V, Agnew M, Bennett J, et al. Joint Strategic Needs Assessment (JSNA): statement of  
37  
38 need 2011. <http://liverpool.gov.uk/D3BF7EE5-C08A-483A-909D-11586E1E478C/FinalDownload/DownloadId-1CF52DF971DC843A6A1DFDF4F5AB74EB/D3BF7EE5-C08A-483A-909D-11586E1E478C/media/100609/Liverpool-PCT-Current-and-Future-Health-and-Social-Care-Needs-2011.pdf> (accessed 8 Jan 2014): Liverpool PCT, 2011.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 13 Krieger N, Waterman PD, Chen JT, et al. Monitoring socioeconomic inequalities in sexually  
51  
52 transmitted infections, tuberculosis, and violence: Geocoding and choice of area-based  
53  
54 socioeconomic measures - The public health disparities geocoding project (US). *Public*  
55  
56

- 1  
2  
3 Health Reports 2003;**118**(3):240-60 doi: Doi 10.1016/S0033-3549(04)50245-5[published  
4  
5 Online First: Epub Date]].  
6  
7  
8 14 Rogers SM, Miller HG, Miller WC, et al. NAAT-identified and self-reported gonorrhoea and  
9  
10 chlamydial infections: different at-risk population subgroups? Sex Transm Dis  
11  
12 2002;**29**(10):588-96  
13  
14  
15 15 Ross JD. Gonorrhoea: to screen or not to screen? Sex Transm Infect 2010;**86**(6):411-2 doi:  
16  
17 10.1136/sti.2010.042804[published Online First: Epub Date]].  
18  
19  
20 16 National Chlamydia Screening Programme. The NCSP: An Overview.  
21  
22 <http://www.chlamydia-screening.nhs.uk/ps/overview.asp> (accessed 8 Jan 2014); , 2013.  
23  
24  
25 17 Department of Health. Healthy lives, healthy people: Improving outcomes and supporting  
26  
27 transparency. 23 January 2012 (available at  
28  
29 [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/263658/29](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/263658/2901502_PHOF_Improving_Outcomes_PT1A_v1_1.pdf)  
30  
31 [01502\\_PHOF\\_Improving\\_Outcomes\\_PT1A\\_v1\\_1.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/263658/2901502_PHOF_Improving_Outcomes_PT1A_v1_1.pdf)) (accessed 8 Jan 2014), 2012  
32  
33  
34 18 Walsh B, Silles M, O'Neill C. The importance of socio-economic variables in cancer  
35  
36 screening participation: a comparison between population-based and opportunistic  
37  
38 screening in the EU-15. Health Policy 2011;**101**(3):269-76 doi:  
39  
40 10.1016/j.healthpol.2011.02.001[published Online First: Epub Date]].  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

|                              | Item No | Recommendation                                                                                                                                                                                    | Reported on page #         |
|------------------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| <b>Title and abstract</b>    | 1       | (a) Indicate the study's design with a commonly used term in the title or the abstract                                                                                                            | 4                          |
|                              |         | (b) Provide in the abstract an informative and balanced summary of what was done and what was found                                                                                               | 4                          |
| <b>Introduction</b>          |         |                                                                                                                                                                                                   |                            |
| Background/rationale         | 2       | Explain the scientific background and rationale for the investigation being reported                                                                                                              | 6                          |
| Objectives                   | 3       | State specific objectives, including any prespecified hypotheses                                                                                                                                  | 7                          |
| <b>Methods</b>               |         |                                                                                                                                                                                                   |                            |
| Study design                 | 4       | Present key elements of study design early in the paper                                                                                                                                           | 7                          |
| Setting                      | 5       | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection                                                                   | 7                          |
| Participants                 | 6       | (a) Give the eligibility criteria, and the sources and methods of selection of participants                                                                                                       | 7                          |
| Variables                    | 7       | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable                                                          | 7-8                        |
| Data sources/<br>measurement | 8*      | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group              | 7-8                        |
| Bias                         | 9       | Describe any efforts to address potential sources of bias                                                                                                                                         | 8                          |
| Study size                   | 10      | Explain how the study size was arrived at                                                                                                                                                         | 8                          |
| Quantitative<br>variables    | 11      | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why                                                                      | 8                          |
| Statistical methods          | 12      | (a) Describe all statistical methods, including those used to control for confounding                                                                                                             | 8-9                        |
|                              |         | (b) Describe any methods used to examine subgroups and interactions                                                                                                                               | 8                          |
|                              |         | (c) Explain how missing data were addressed                                                                                                                                                       | 8                          |
|                              |         | (d) If applicable, describe analytical methods taking account of sampling strategy                                                                                                                | N/A                        |
|                              |         | (e) Describe any sensitivity analyses                                                                                                                                                             | N/A                        |
| <b>Results</b>               |         |                                                                                                                                                                                                   |                            |
| Participants                 | 13*     | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 9 and<br>Tables<br>1 and 2 |
|                              |         | (b) Give reasons for non-participation at each stage                                                                                                                                              | N/A                        |
|                              |         | (c) Consider use of a flow diagram                                                                                                                                                                | N/A                        |
| Descriptive data             | 14*     | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders                                                          | 8 and<br>Tables<br>1 and 2 |
|                              |         | (b) Indicate number of participants with missing data for each variable of interest                                                                                                               | 8 and<br>Table 2           |
| Outcome data                 | 15*     | Report numbers of outcome events or summary measures                                                                                                                                              | 8 and<br>Table 2           |
| Main results                 | 16      | (a) Give unadjusted estimates and, if applicable, confounder-adjusted                                                                                                                             | Table 2                    |



|                          |    |                                                                                                                                                                            |         |
|--------------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
|                          |    | estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included                                     |         |
|                          |    | (b) Report category boundaries when continuous variables were categorized                                                                                                  | Table 2 |
|                          |    | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period                                                           | N/A     |
| Other analyses           | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses                                                                             | N/A     |
| <b>Discussion</b>        |    |                                                                                                                                                                            |         |
| Key results              | 18 | Summarise key results with reference to study objectives                                                                                                                   | 18—19   |
| Limitations              | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias                 | 18      |
| Interpretation           | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 18—19   |
| Generalisability         | 21 | Discuss the generalisability (external validity) of the study results                                                                                                      | 19      |
| <b>Other information</b> |    |                                                                                                                                                                            |         |
| Funding                  | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based              | 20      |

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).